Przejdź do
Wybierz wielkość
| Rozmiar/SKU | Dostępność | Cena netto |
|---|
Informacje o tej pozycji
biological source
human brain
manufacturer/tradename
ECACC
packaging
tube of 5 μg 86022702-DNA-5UG, pkg of vial of cells 86022702-1VL
growth mode
Adherent
karyotype
Not specified
morphology
Not specified
products
Not specified
receptors
Not specified
technique(s)
cell culture | mammalian: suitable
relevant disease(s)
cancer
shipped in
dry ice
storage temp.
−196°C
Application
Biochem/physiol Actions
CSF1PO: 10
D13S317: 11
D16S539: 12,13
D5S818: 11
D7S820: 10
THO1: 6
TPOX: 11
vWA: 14
Preparation Note
Other Notes
1 of 1
Ta pozycja | |||
|---|---|---|---|
| description NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA, 86022702, human brain, Not specified | description NOTE: Both the cell line and DNA from the cell line may be available for this product. Please choose -1VL or VIAL for cells, or -DNA-5UG for DNA, 86022703, human brain, Not specified | description Prestige Antibodies® Powered by Atlas Antibodies, clone CL2852, purified immunoglobulin, buffered aqueous glycerol solution | description Prestige Antibodies® Powered by Atlas Antibodies, clone CL2858, purified immunoglobulin, buffered aqueous glycerol solution |
| biological source human brain | biological source human brain | biological source mouse | biological source mouse |
| relevant disease(s) cancer | relevant disease(s) cancer | relevant disease(s) - | relevant disease(s) - |
| morphology Not specified | morphology Not specified | morphology - | morphology - |
| growth mode Adherent | growth mode Adherent | growth mode - | growth mode - |
| products Not specified | products Not specified | products - | products - |
| storage temp. −196°C | storage temp. −196°C | storage temp. −20°C | storage temp. −20°C |
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.


